It is made available under a	CC-BY	4.0 International	license.
------------------------------	-------	-------------------	----------

1	Title: A deep learning transformer model predicts high rates of undiagnosed rare disease in large electronic health
2	systems
3	
4	Authors: Daniel M. Jordan, Ha My T. Vy, Ron Do [*] .
5	
6	Affiliation: Center for Genomic Data Analytics, Charles Bronfman Institute for Personalized Medicine,
7	Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,
8	NY, USA
9	* Corresponding author
10	
11	Correspondence:
12	Ron Do, PhD
13	Annenberg Building, Floor 18 Room 80A
14	1468 Madison Ave
15	New York, NY-10029
16	Phone Number: 212-241-6206 Fax Number: 212-849-2643
17	Email: ron.do@mssm.edu
18	
19	

It is made available under a CC-BY 4.0 International license .

20 Abstract

21 It is estimated that as many as 1 in 16 people worldwide suffer from rare diseases. Rare disease patients face difficulty finding diagnosis and treatment for their conditions, including long diagnostic odysseys, 22 23 multiple incorrect diagnoses, and unavailable or prohibitively expensive treatments. As a result, it is likely 24 that large electronic health record (EHR) systems include high numbers of participants suffering from 25 undiagnosed rare disease. While this has been shown in detail for specific diseases, these studies are 26 expensive and time consuming and have only been feasible to perform for a handful of the thousands of known rare diseases. The bulk of these undiagnosed cases are effectively hidden, with no straightforward 27 way to differentiate them from healthy controls. The ability to access them at scale would enormously 28 29 expand our capacity to study and develop drugs for rare diseases, adding to tools aimed at increasing 30 availability of study cohorts for rare disease. In this study, we train a deep learning transformer algorithm, 31 RarePT (Rare-Phenotype Prediction Transformer), to impute undiagnosed rare disease from EHR 32 diagnosis codes in 436,407 participants in the UK Biobank and validated on an independent cohort from 33 3,333,560 individuals from the Mount Sinai Health System. We applied our model to 155 rare diagnosis 34 codes with fewer than 250 cases each in the UK Biobank and predicted participants with elevated risk for 35 each diagnosis, with the number of participants predicted to be at risk ranging from 85 to 22,000 for different diagnoses. These risk predictions are significantly associated with increased mortality for 65% 36 37 of diagnoses, with disease burden expressed as disability-adjusted life years (DALY) for 73% of diagnoses, and with 72% of available disease-specific diagnostic tests. They are also highly enriched for 38 known rare diagnoses in patients not included in the training set, with an odds ratio (OR) of 48.0 in cross-39 validation cohorts of the UK Biobank and an OR of 30.6 in the independent Mount Sinai Health System 40 41 cohort. Most importantly, RarePT successfully screens for undiagnosed patients in 32 rare diseases with 42 available diagnostic tests in the UK Biobank. Using the trained model to estimate the prevalence of 43 undiagnosed disease in the UK Biobank for these 32 rare phenotypes, we find that at least 50% of patients remain undiagnosed for 20 of 32 diseases. These estimates provide empirical evidence of a high 44

It is made available under a CC-BY 4.0 International license .

- 45 prevalence of undiagnosed rare disease, as well as demonstrating the enormous potential benefit of using
- 46 RarePT to screen for undiagnosed rare disease patients in large electronic health systems.

47

It is made available under a CC-BY 4.0 International license .

48 Introduction

49 Rare diseases, also known as orphan diseases, are defined by the European Union as those affecting fewer 50 than one in 2,000 people, and in the United States as those affecting fewer than 200,000 people nationwide^{1,2}. Rare diseases are collectively very common, and it is estimated that as many as 1 in 16 51 52 people (6.2%) suffer from one or more rare diseases³. This makes them a serious public health concern, as 53 rare disease patients are far less likely to receive accurate diagnoses or, once diagnosed, to have access to effective treatments for their conditions⁴⁻⁶. This is due to the difficulty of studying rare diseases, a scarcity 54 55 of clinical expertise and diagnostic methods, as well as the unprofitability of developing drugs targeting them. In fact, many of these diseases are so understudied and underdiagnosed that we do not know with 56 any certainty what their true prevalence is, and how many undiagnosed patients there may be³. One of the 57 58 primary reasons for all these problems is the difficulty of finding large enough populations of patients to conduct well-powered studies on these diseases, either in the context of basic or translational research or 59 60 in the context of drug trials. This is a pressing problem, and tools such as MatchMaker Exchange, which help researchers match similar cases to increase sample size for studies of rare diseases, are widely used⁷⁻ 61 ⁹. Further development of these tools is also an active area of research, including expanding them to 62 include comparisons of phenotypic features mined from electronic health records (EHR) or imaging data⁹⁻ 63 64 ¹². These tools are vital for rare disease research because undiagnosed rare disease patients masquerade as 65 healthy controls, making them invisible and inaccessible to researchers unless they can be revealed. There is an urgent need for new approaches to reveal people suffering from hidden rare diseases in research and 66 drug trial cohorts, and in clinical practice. 67

In this study, we present such an approach, using a deep learning transformer model trained on EHR data. Artificial intelligence (AI) language models based on the transformer architecture, such as BERT ("Bidirectional Encoder Representations from Transformers" and GPT ("Generative Pretrained Transformers"), have proved very successful at learning the relationships between concepts in natural languages^{13,14}. Transformer models have also been successfully applied to problems in biology that are

It is made available under a CC-BY 4.0 International license .

73	not directly related to language processing in methods such as AlphaFold-2, AlphaMissense, DeepMAPS,
74	and Enformer ^{15–18} . One of the strength of the transformer architecture is that, with appropriate
75	tokenization and training schemes, transformers can correctly model concepts that are extremely rare, and
76	some transformer-based models have been shown to define a new word after seeing it only a small
77	number of times ^{19–22} . We have designed a modified transformer architecture to model phenotypic concepts
78	based on phenotypes derived from structured diagnosis codes in electronic health records (EHR), along
79	with a modified training procedure designed to maximize power to screen for missing rare diagnoses. The
80	resulting model, RarePT (Rare-Phenotype Prediction Transformer), was trained on EHR data from
81	436,407 individuals from the UK Biobank and validated on an independent cohort from 3,333,560
82	individuals from the Mount Sinai Health System in New York City, USA (Table 1). RarePT shows
83	remarkable power to recapitulate rare diagnoses, which is robust across different racial and ethnic groups,
84	different hospitals with different coding practices, and even different countries with different health care
85	standards and coding vocabularies. It also detects UK Biobank participants with undiagnosed rare disease,
86	enabling empirical measurement of the true prevalence of undiagnosed cases for rare diseases.

87 **Results**

88 *Model training and cross-validation*

89 We implemented a transformer model with a self-attention mechanism similar to AI language 90 models such as BERT and GPT, along with a "masked diagnosis modeling" training objective by analogy to the "masked language modeling" objective used by some of these language models¹⁹. In this approach, 91 92 training examples consist of complete sequences with a single token removed, and the model is trained to 93 reconstruct the missing token. In the natural language processing case, this is a sequence of words with a 94 single word removed; in our case, it is a participant record with a single diagnosis removed (Figure 1a). The model learns the meanings of tokens based on the context they appear in, resulting in embeddings 95 that cluster tokens that commonly appear together and tokens that appear in similar context. Models 96 97 trained with this objective are known to learn informative embeddings even for very rare tokens in many

It is made available under a CC-BY 4.0 International license .

98 cases¹⁹⁻²². We made use of this feature to train a model to predict rare diagnoses, a critical need due to
99 underdiagnosis and understudying of rare diseases.

An additional advantage of the masked diagnosis modeling training objective for rare tokens is 100 that it allows us to weight the importance of tokens to the training objective independent of their 101 102 prevalence in the training corpus. This is because each training example specifies which token the model 103 must predict correctly to be scored as successful, and the model is not necessarily required to predict every token in each example. The importance of each token to the training objective is determined by how 104 105 many examples have it as the masked token. In order to prevent very common diagnoses from dominating the learned embeddings, we limited training examples to a fixed number of cases and controls for each 106 107 diagnosis. While we used 100 cases and controls for each diagnosis, in principle this is a tunable 108 parameter of the training process. Lower values allow rarer diagnoses to be included, while higher values 109 increase the amount of training data available.

In this study, we express diagnoses as phecodes²³. We determined phecodes from ICD-10 codes for 436,407 participants in the UK Biobank based on a standard mapping²⁴. We then filtered out all phecodes with fewer than 100 cases and controls and constructed a training dataset consisting of 100 randomly selected cases and 100 randomly selected controls for each phecode. The resulting training set consisted of 259,400 training examples representing 1,297 query phecodes and 111,331 unique participants. For each training example, input data included the following features:

- 116 1. The identity of the query phecode
- 117 2. All other phecodes for which the participant is considered a case
- 118 3. Age at recruitment
- 119 4. Sex reported from recruitment

These training examples were split into 5 subsamples for cross-validation, stratified so that each
participant appeared in only one split and so that each split contained a similar number of cases and

It is made available under a CC-BY 4.0 International license .

122 controls. Neural network architecture and other training hyperparameters were tuned on the training data 123 for each split using the Hyperband algorithm²⁵, and then the tuned model was trained on the same data 124 and tested on the held-out test data; see Methods for details of model tuning and training parameters. The 125 final tuned architecture is shown in in Figure 1b; details of training performance can be found in 126 Supplementary Figure S1 and Supplementary Table S1. In general, the models performed well on the 127 test data and showed only minor loss of performance between training and test data.

128 RarePT predicts rare diagnoses in the UK Biobank

To test the ability of the trained model to predict rare diagnoses, we first selected all phecodes 129 appearing in fewer than 1 in 2,000 UK Biobank participants, corresponding to the definition of rare 130 diseases used by the European Union². There were 155 rare phecodes meeting this criterion, shown in 131 132 **Supplementary Table S2**. Not all phecodes that are rare in the UK Biobank represent phenotypes that meet the definition of rare diseases in the general population. One reason for this is the known bias of the 133 134 UK Biobank population towards healthier and older participants^{26–28}, which reduces the apparent 135 prevalence of many diseases, especially severe diseases with early onset. For example, phecode 315.3 "mental retardation" appears in fewer than 200 participants in the UK Biobank even though the disorders 136 137 it represents are much more common in the general population, which is likely because severe childhood disorders are underrepresented in this cohort of healthy adults. It is also likely that many of these rare 138 139 phecodes correspond to diagnosis codes that rarely appear in electronic health records (EHR) despite the conditions they refer to being common. Likely examples of this include 367.4 "presbyopia" and 523.1 140 "gingivitis." Nevertheless, even if not all of these phecodes represent phenotypes that are rare in the 141 general population, they do represent phenotypes that are rare in the data used to train our model, and the 142 143 model's performance on these phecodes is informative about how our methodology handles rare phenotypes. In total, 21,636 of the 436,407 participants tested have one or more of these rare diagnoses, 144 145 giving them a cumulative prevalence of 5.0%. This matches the estimated cumulative prevalence of 1.5-

It is made available under a CC-BY 4.0 International license .

6.2% for rare diseases in the general population³, suggesting that our selection of rare phecodes does
accurately capture the population distribution of rare diseases.

After training on a 111,311-participant subset of UK Biobank data constructed to force each 148 phecode to have prevalence of 50%, we measured RarePT's performance in the full UK Biobank dataset 149 150 of 436,407 participants. We arbitrarily chose a threshold of 0.95 in the model's probability score output, 151 so that participants with a score of 0.95 or higher in a given phecode were treated as positive predictions for that phecode. With this definition, across all five cross-validated models, we generate specific positive 152 predictions for each of our 155 rare phecodes. The number of positive predictions varied by phecode, 153 ranging between 85 and 22,000 with a median of 2,135 positive predictions per phecode (Supplementary 154 155 Table 3). These positive predictions are broadly distributed across participants rather than being 156 concentrated in a small group of unhealthy participants, with no participant receiving more than 29 positive predictions and 41% of participants (177,484) receiving a positive prediction for at least one of 157 158 the 155 phecodes. Figure 2 shows the performance of the 5 cross-validated models at predicting rare 159 phecodes in the full dataset, excluding each model's training data. We measured prediction performance using diagnostic odds ratio (OR), defined as the ratio between the odds of a participant having a diagnosis 160 given a positive prediction from the model and the odds of a participant having a diagnosis given a 161 negative prediction from the model. The median OR for a positive prediction across all 155 rare phecodes 162 163 and across the five models trained in cross-validation was 48.0. Some specific phecodes reached a median OR over 20,000, and the lowest median OR for any rare phecode was 5.13 (Figure 2a, Supplementary 164 Table S3). These values compare favorably to many commonly used diagnostic tests, where diagnostic 165 166 odds ratios in the range of 20-50 are considered very good^{29,30}. Similarly, the positive predictive value 167 (PPV) for cases is nearly 40% for some phecodes, which is well within the range of a useful screening test (Supplementary Figure S2, Supplementary Table S3). Because PPV depends on the prevalence of the 168 condition within the test population, we expect this number to increase further when applying this method 169 170 in situations where the prior expectation of encountering a given diagnosis is increased, such as in

It is made available under a CC-BY 4.0 International license .

patients with undiagnosed rare conditions or patients who carry rare genetic variants. Importantly, the predictions are able to distinguish not only between cases and controls but also between cases for one phecode and cases for another, indicating that RarePT is making specific predictions for each phecode rather than measuring general health (Figure 2b).

175 Model trained on UK Biobank is predictive in an independent EHR cohort

176 We applied the trained RarePT model to an independent dataset derived from the Mount Sinai Data Warehouse (MSDW), consisting of anonymized EHR for a cohort of 3,333,560 patients seen in the 177 178 Mount Sinai Health System in New York City. We determined phecodes for these participants in the same way as for the UK Biobank participants, but using a mapping designed for the US clinical modification to 179 ICD-10 (ICD-10CM) rather the international standard ICD-10 system used by UK hospitals²⁴. 151 of the 180 181 155 phecodes determined to be rare in the UK Biobank cohort were present in the MSDW cohort. As a health system based cohort, this cohort is expected to be significantly less healthy than the UK Biobank³¹, 182 183 and therefore we expect most phecodes to have higher prevalence than in the UK Biobank cohort. 184 Nevertheless, a majority of the rare phecodes we tested (86/151; 57%) still had prevalence less than 1 in 2,000 in the MSDW cohort (Supplementary Table S2). Likewise, we expect more positive predictions 185 186 for each phecode, both due to the dataset being over 7-fold larger and due to participants being less healthy in general. 187

188 For these phecodes in the MSDW cohort, RarePT produced between 100 and 721,000 positive 189 predictions per phecode, with a median of 11,500, and produced at least one positive prediction in 47% of participants (1,518,757). These predictions performed similarly to the predictions for the UK Biobank 190 191 cohort, with a median OR of 30.6 across all 151 phecodes (Figure 2a, Supplementary Table S4). 192 Performance for individual phecodes was also strongly correlated across the two datasets (Pearson r = 0.456, $p = 5.03 \times 10^{-40}$, t-test; Figure 2c). The fact that performance is similar across the two datasets 193 194 indicates that RarePT's predictions are based on features that are robust to different methodologies for sample ascertainment and data collection, rather than features that are only informative in the specialized 195

It is made available under a CC-BY 4.0 International license .

context of the UK Biobank. This replication is especially remarkable given the extensive differences
between the two cohorts: in addition to one being a population-based cohort of healthy volunteers and the
other being a health system cohort, these cohorts are also from different countries with different standard
medical practices, different billing structures and coding systems, and different distributions of race,
ethnicity, and genetic ancestry. This indicates the wide applicability of the RarePT method and suggests
that its performance does not depend on specific features of diagnosis coding in a particular health
system.

203 Rare disease predictions are associated with mortality, disease burden, and known diagnostic biomarkers

To further demonstrate that RarePT is capturing clinically relevant signals of disease rather than 204 205 bioinformatic artifacts related to diagnosis coding, we performed regression analyses to test the 206 association of positive predictions with mortality, disability, and, where available, known diagnostic biomarkers. We retrieved the latest mortality data for UK Biobank participants as of October 2023, and 207 208 performed Cox proportional hazard regression to test whether a positive prediction is associated with 209 mortality, controlling for age, sex, and self-reported ethnicity. 101 phecodes (65% of phecodes tested) had a significant association (p < 0.05) with increased mortality, of which 93 (60%) remained significant after 210 Bonferroni correction for 155 phecodes (p < 0.00032). The median phecode had a regression coefficient 211 of 0.70, corresponding to a hazard ratio of 2.01, or a twofold increase in mortality rate (Supplementary 212 Table S5). 213

Next, we estimated Disability Adjusted Life Years (DALY) and its two components, Years of Life
Lost (YLL) and Years Living with Disability (YLD), for 80 conditions for all UK Biobank participants³².
These measurements represent the number of years lost to both mortality and disability as a result of
illness and are used as a measure of disease burden, particularly in the Global Burden of Disease study³³.
We performed linear regressions with DALY, YLD, and YLL as the dependent variables to test whether a
positive prediction is associated with greater disease burden. In all of these regressions, we controlled for
age, sex, and self-reported ethnicity. 113 phecodes (73% of phecodes tested) had a significant association

It is made available under a CC-BY 4.0 International license .

(p < 0.05) with increased estimated DALY, and 106 (68%) remained significant after Bonferroni
correction for 155 phecodes (p < 0.00032). 134 phecodes (87%) had a significant association with
increased estimated YLD individually, 133 (86%) after Bonferroni correction; 110 phecodes (71%) had a
significant association with increased estimated YLL individually, 106 (68%) after Bonferroni correction.
For the median phecode, a positive prediction was associated with an increase in estimated DALY of 1.1
years (Supplementary Table S5).

To identify diagnostic biomarkers, we used the SNOMED-CT vocabulary of clinical terms^{34,35} to 227 228 identify phenotypes whose clinical definition includes laboratory tests that are available for large numbers of participants in the UK Biobank. We identified 75 defined relationships between 32 rare phecodes and 229 230 23 laboratory tests (Supplementary Table S6). These tests were performed as part of the UK Biobank 231 recruitment process and were generally not returned to participants or their physicians, so the availability of a test result does not indicate that it was ordered by a physician and the result of a test was not visible 232 233 to the physicians responsible for entering diagnoses into the participants' EHR. Since RarePT makes its 234 predictions using only diagnosis codes and has no access to physician-ordered laboratory tests except through diagnosis codes, this means our model's predictions are independent of these test results. This is 235 236 in contrast to health system based cohorts, including our MSDW cohort, where diagnostic tests are ordered and administered in the context of treating the patient, so that the presence and timing of a test are 237 informative about the judgment of the health care providers and the test result forms part of the diagnostic 238 criteria³⁶. 239

For each of these 75 relationships, we performed a logistic regression to test whether a confident case prediction is associated with abnormal test results, again controlling for age, sex, and ethnicity. 54 of these regressions, representing 72% of these relationships, had a result that was in the expected direction and statistically significant (p < 0.05), and 45 (60%) remained significant after Bonferroni correction for 75 regressions (p < 0.00067). The median regression coefficient was 0.57, corresponding to an OR of 1.77. In other words, for the median diagnostic test, a participant with a positive prediction from RarePT

It is made available under a CC-BY 4.0 International license .

246 had 77% higher odds of having an abnormal test result. In 100 random permutations of phecode-247 laboratory test relationships, no permutation showed as many Bonferroni-significant associations (p < 0.01) (Figure 3a, Supplementary Table S7-S8). We additionally performed linear regression for each of 248 249 these relationships, testing for a relationship between the model prediction and the quantitative test result. 250 43 of these regressions, representing 57% of these relationships, had a result that was in the expected 251 direction and statistically significant, and 38 (51%) remained significant after Bonferroni correction. 252 Again, 0 out of 100 random permutations showed as many Bonferroni-significant associations (p < 0.01) 253 (Figure 3a, Supplementary Table S7-8).

Taken together, these analyses demonstrate that positive predictions from RarePT do not merely predict diagnosis codes for rare diseases, but also capture clinically and biologically relevant features relevant to the diagnoses and to health outcomes more generally.

257 Disease predictions suggest high rates of underdiagnosis for rare diseases

It has been demonstrated for many diseases, both rare and common, that only a fraction of 258 affected individuals actually have a diagnosis annotated in their EHR³⁷⁻⁴³. As a result, it is likely that 259 260 many of the participants annotated as controls in our dataset are actually undiagnosed cases. In order to 261 evaluate RarePT's performance in these undiagnosed cases, we repeated the regression analyses of 262 mortality and estimated DALY restricting to participants labelled as controls, so that participants who had 263 the corresponding diagnosis in their EHR were excluded. The mortality analysis produced similar results 264 after excluding known diagnosed cases: 101 phecodes (67% of phecodes tested) had a significant association (p < 0.05) with increased mortality, of which 93 (60%) remained significant after Bonferroni 265 266 correction for 155 phecodes (p < 0.00032). The median regression coefficient for the proportional hazard 267 regression on mortality was 0.86, corresponding to a hazard ratio of 2.4. The DALY analysis also 268 produced similar results: 114 phecodes (74% of phecodes tested) had a significant association (p < 0.05) 269 with increased estimated DALY, and 106 (68%) remained significant after Bonferroni correction for 155 phecodes (p < 0.00032). 131 phecodes (85%) had a significant association with increased estimated YLD 270

It is made available under a CC-BY 4.0 International license .

individually, 126 (81%) after Bonferroni correction; 110 phecodes (71%) had a significant association
with increased estimated YLL individually, 104 (67%) after Bonferroni correction. For the median
phecode, a positive prediction was associated with an increase in DALY of 1.5 years in controls. These
results demonstrate that RarePT predictions are associated with health outcomes even when a diagnosis is
not present in the EHR, suggesting that RarePT identifies clinically relevant features even in undiagnosed
individuals and may be identifying undiagnosed cases.

We next repeated the logistic regression analysis testing RarePT predictions against abnormal test 277 278 results. As expected, excluding known cases reduced the significance of many, but not all, of these 279 regressions. Nevertheless, 47 of these regressions, representing 63% of these relationships, had a result 280 that was in the expected direction and statistically significant (p < 0.05), and 36 (48%) remained 281 significant after Bonferroni correction for 75 regressions (p < 0.00067). The median regression coefficient was 0.45, corresponding to an OR of 1.57. As with the regressions that included cases, in 100 random 282 283 permutations of phecode-laboratory test relationships, no permutation showed as many Bonferroni-284 significant associations (p < 0.01) (Figure 3b, Supplementary Tables S10-S11). We also repeated the linear regression analysis testing RarePT predictions against quantitative test results, excluding both 285 286 known cases and participants with abnormal test results. 29 of these regressions, representing 39% of these relationships, had a result that was in the expected direction and statistically significant, with 21 287 (28%) remaining significant after Bonferroni correction. Again, 0 out of 100 random permutations 288 showed as many Bonferroni-significant associations (Figure 3b, Supplementary Tables S10-S11). This 289 analysis supports the conclusion that RarePT's predictions are predictive not only of existing rare 290 291 diagnoses, but also of undiagnosed cases.

In order to estimate the number of these undiagnosed cases that exist in the UK Biobank dataset, we first identified participants whose test results show that they are unlikely to be undiagnosed cases for a particular phecode. We defined this category of "confirmed controls" as participants whose test results fell within 1 standard deviation of the population mean for a particular test. This is possible because these

It is made available under a CC-BY 4.0 International license .

tests were administered in an unbiased way to a large cross-section of participants, and the presence of a negative test result does not indicate that a physician ordered the test to rule out a suspected diagnosis. We then measured RarePT's performance based on these confirmed controls and the observed diagnosed cases. Assuming that RarePT performs similarly for unconfirmed controls and undiagnosed cases as for confirmed controls and diagnosed cases, the prevalence of undiagnosed cases can be estimated by comparing the expected number of false positives among unconfirmed controls to the actual number of unconfirmed controls predicted as cases (Figure 3c, Supplementary Note 1).

We estimated the number of undiagnosed cases and the fraction of actual cases that are 303 undiagnosed for each rare phecode with an associated diagnostic test, using a bootstrap sampling 304 305 procedure to obtain 95% confidence intervals (Figure 3d-e, Supplementary Table S12). The estimated 306 proportion of undiagnosed cases varied widely by phecode, but nearly three-quarters of phecodes tested (23/32 = 72%) had an estimate greater than 20%. Even more remarkably, nearly two-thirds of phecodes 307 308 tested (20/32 = 63%) had more undiagnosed cases than diagnosed cases, and over a third (12/32 = 38%)309 had a bootstrap confidence interval entirely above the number of diagnosed cases. The median estimated rate of underdiagnosis across all phecodes tested was 83%, meaning that we estimate 83% of cases are 310 311 undiagnosed for the median rare phecode. This analysis suggests that there are a very large number of undiagnosed cases of rare diseases in large population biobanks like the UK Biobank. Furthermore, it 312 suggests that RarePT is able to predict some of these hidden undiagnosed cases, allowing them to be 313 identified for the first time. 314

315 Discussion

Here we present RarePT, a transformer-based phenotype prediction method designed to predict rare disease diagnoses based on diagnosis codes present in a patient's electronic health records (EHR). We apply this method to predicting rare disease in the UK Biobank, and find that a very large fraction of rare disease cases are undiagnosed. Our method adds to a growing collection of phenotype prediction methods that use machine learning to clean and extend EHR data for downstream analysis ^{44–48}. Our method is

It is made available under a CC-BY 4.0 International license .

321 distinct from other approaches in that it focuses specifically on rare disease. It is typically difficult to train 322 machine learning approaches for rare disease because the low prevalence of these diseases limits the availability of training data. We overcame this difficulty using a "masked diagnosis modeling" approach 323 inspired by the approaches used to train AI language models such as BERT¹⁹. This approach learns about 324 325 diagnoses by identifying which other diagnoses are most likely to appear in similar contexts, allowing it to learn informative features even for rare diagnoses. In addition to this training strategy, we reweighted 326 327 our training data to give equal importance to rare and common diagnoses, boosting our power to predict 328 rare diseases.

329 The trained RarePT model is highly predictive of a wide range of rare disease diagnoses, showing 330 the promise of our deep learning approach as a screening test for specific rare diagnoses that could be 331 applied in a clinical setting in the future. Across all rare phecodes, RarePT's predictions are associated with a median diagnostic odds ratio (OR) of 48.0 in cross-validation – that is, participants predicted to 332 333 have a rare diagnosis by our model are 48.0 times more likely to have that diagnosis in their EHR 334 compared to participants without such a prediction. For some specific rare diseases, this performance is even better, with the top 10% of diagnoses achieving a diagnostic OR over 350 in cross-validation and the 335 336 top 5% achieving a diagnostic OR over 1,500 in cross-validation. These values compare favorably to many diagnostic tests currently in standard clinical use. Remarkably, this performance is replicated in a 337 338 completely independent cohort of patients at the Mount Sinai Health System in New York, which represents not only a different health system but an entirely different country with different medical 339 practices and different standards for diagnostic coding and billing. The ability to predict rare disease 340 diagnoses in this independent cohort shows the power and transferability of this approach. 341

In addition to successfully predicting rare diagnoses in participants' EHR, RarePT also provides new evidence that a substantial number of participants may suffer from rare diseases without a diagnosis appearing in the EHR. This reinforces the known fact that many diagnoses are missing from EHR, due to biases in diagnosis, inconsistent use of billing codes, incomplete or fragmented patient records, and other

It is made available under a CC-BY 4.0 International license .

issues⁴⁹⁻⁵³. This effect has previously been quantified for a variety of diseases, both common and rare, and 346 often found to be substantial. For example, biobank studies have estimated that up to 75% of patients with 347 erythropoetic protoporphyria (EPP)³⁹, approximately 85% of patients with familial 348 hypercholesterolemia⁵⁴, and approximately 90% of patients with glycated hemoglobin (HbA_{1c}) levels 349 indicating diabetes⁴² remain undiagnosed. This is especially problematic for rare diseases, due to the 350 known difficulty of correctly diagnosing rare diseases and the long diagnostic odyssey experienced by 351 many rare disease patients^{3-6,55}. We hypothesized that RarePT would correctly predict many of these 352 undiagnosed cases, causing them to appear as false positives despite actually being correct predictions. 353 354 For rare diseases where relevant biomarkers were available, these biomarkers consistently showed a significant excess of abnormal values and more extreme values within the normal range in individuals 355 predicted positive by RarePT, supporting the hypothesis that many of RarePT's predictions are actually 356 undiagnosed cases. Consistent with literature estimates for common diseases, we estimate the prevalence 357 358 of undiagnosed cases in rare diseases to be remarkably high: 72% of phecodes we tested appeared to have

an underdiagnosis rate above 20%, and 63% of phecodes we tested were consistent with a majority of

360 cases being undiagnosed. While these numbers may be higher than the true rate in the general population

361 due to the UK Biobank being biased towards healthier participants, who are less likely to seek out and

receive diagnoses than the general population 26,27,31 , both the existence and magnitude of this

phenomenon are consistent with previous results on underdiagnosis of diseases in EHR. The RarePT
model allows us to measure this underdiagnosis systematically across a range of rare diseases, which has
not previously been possible, as well as to identify specific individuals who may be suffering from rare
disease and have a missing or incorrect diagnosis.

There are many potential practical applications for RarePT. One of these is as a phenotype imputation step in a data preprocessing pipeline for downstream bioinformatic analysis, which has previously been unavailable for rare diagnoses^{31,56,57}. Another application is in collecting rare disease cohorts for research studies or drug trials. Due to the rarity of rare diseases, identifying multiple patients

It is made available under a CC-BY 4.0 International license .

with the same disease is a pressing problem in rare disease research, and the international research
community has developed several tools to address it^{7–9}. RarePT can augment or support these tools by
allowing researchers to rapidly search EHR for patients who are likely to have a particular disease or
patients who are phenotypically similar to another specific patient. It also has the potential to be
developed into a clinical screening test for rare diseases, particularly in patients with a specific risk factor
such as family history of disease or a genetic risk allele.

There are several limitations and areas of further development for this approach. First, phecodes 377 378 are designed for phenome-wide association (PheWAS) studies primarily targeting common phenotypes 379 and are not specifically designed to target rare diseases. While some specific rare phenotypes may be 380 inaccessible to RarePT for this reason, recent studies have shown that vocabularies for common disease, including phecodes, do capture information about rare phenotypes $^{58-60}$, and we identified phecodes that 381 were rare in both the UK Biobank and MSDW cohorts. Future versions of this approach could increase 382 383 the resolution for rare phenotypes by using phenotype ontologies designed to represent rare diseases, such as the Human Phenotype Ontology (HPO)⁶¹ or the OrphaNet disease ontology⁶². However, there are 384 tradeoffs involved in this choice. Using a more fine-grained vocabulary for rare disease would 385 386 dramatically increase the complexity of the model and its computational requirements. The analyses we present here require generation of millions of phenotype predictions, which took several hours of GPU 387 388 time under the current RarePT architecture and would quickly become infeasible if the phenotype encoding used a complex hierarchical structure with a vocabulary many times larger. Choosing a 389 390 phenotype encoding scheme that can more precisely capture rare phenotypes could also harm the model's 391 ability to capture information about rare and common disease in the same vocabulary, which may reduce 392 the power of the model for rare disease and its transferability to other cohorts beyond its training set. Second, the ICD-10 diagnosis codes we use to derive phecodes are known to be noisy and 393 unreliable^{52,63,64}. We have relied on established methods for automated phenome-wide phenotyping, many 394

395 of which use diagnosis codes in spite of their limitations because more reliable sources of data are either

It is made available under a CC-BY 4.0 International license .

difficult to access in an automated way or are not available phenome-wide^{31,53}. This is particularly true for 396 397 rare diseases, due to the difficulty of finding specialized experts who are capable of reviewing individual patient charts in detail to arrive at a confident diagnosis, particularly at scale^{65–67}. In spite of this, the use 398 of these automated phenotyping approaches could be a concern in our analysis of undiagnosed cases, 399 400 since both our identification of participants with a disease diagnosis and our identification of patients with abnormal test results are based on these potentially unreliable automated procedures. It is possible that 401 402 some of the supposedly undiagnosed cases we identified were actually diagnosed cases where the 403 diagnosis escaped detection by our automated phenotyping process. It is also possible that the availability 404 of certain test results and not others biased our analysis towards specific categories of phenotypes that are 405 not representative of rare diseases in general. For example, blood disorders and metabolic disorders 406 appear to be overrepresented among phenotypes with available diagnostic tests, while neoplasms and neurological disorders are entirely absent (Supplementary Table S6). However, while diagnosis rates 407 408 may differ by category, there is no reason to suppose that categories with greater availability of diagnostic 409 tests are diagnosed at a lower rate than those with less availability of diagnostic tests. Indeed, if anything, 410 the availability of simple diagnostic tests should increase the rate of diagnosis, making our estimates conservative. It is likely that we could make more reliable determinations of both diagnosis status and 411 412 true phenotype by making use of other features available in the EHR, such as lab results, vitals, 413 medications, or unstructured physician's notes. We chose not to include these features in this analysis to avoid circularity in training and analysis, as the diagnoses contained in the EHR are informed by the lab 414 415 results, vitals, and physician's notes from the same EHR. Without careful insulation of these different 416 modalities of data, any trained model or statistical analysis is likely to simply recapitulate the physician's 417 diagnostic criteria without gaining any predictive power for undiagnosed patients, a problem which RarePT avoids by excluding these redundant data sources. Previous studies have also identified 418 undiagnosed cases using a longitudinal study design with direct physician involvement^{40,41}. RarePT could 419 420 facilitate this kind of analysis for specific diagnoses in future studies, following up on this broad automated analysis with in-depth analysis of individual diseases incorporating specific clinical expertise. 421

It is made available under a CC-BY 4.0 International license .

422 Finally, there are many opportunities to improve on our model architecture. Deep learning and AI 423 is a rapidly evolving field, and the transformer-based architecture we used for this analysis may not be the optimal way to learn the semantic structure of EHR diagnoses. Recent studies have proposed new ways of 424 425 derived phenotype embeddings, including extracting them from curated knowledge graphs or from general-purpose large language models pretrained on non-EHR data⁶⁸⁻⁷⁰. There are also a variety of 426 approaches that have been used to process time series data from EHR in machine learning applications. 427 including neural network models designed for time series data such as recurrent neural networks and 428 using pretrained large language models to process EHR^{71,72}. While incorporating newer and more 429 430 sophisticated approaches may improve the model, they may also promote overfitting and reduce transferability of the model across health systems and datasets, as well as slowing down training and 431 432 prediction. RarePT is both transferable and tractable, essential properties for a method designed to process large health system datasets. 433

434 In this paper we have shown that our deep learning phenotype prediction approach, RarePT, is 435 capable of modeling and predicting rare disease diagnoses on a phenome-wide basis, with performance that compares favorably to diagnostic screening tests used in clinical settings. Remarkably, RarePT 436 437 achieves this performance not only in held-out segments of the UK Biobank cohort it was trained on, but also on an entirely separate cohort of patients in the Mount Sinai Health System in New York City. This 438 439 demonstrates that the predictive features RarePT uses are not specific to the UK Biobank, but are robust to differences in recruitment strategy, differences in race and ethnicity, and even differences in medical 440 practices and billing procedures between countries. In addition to capturing specific diagnoses, RarePT 441 predictions also predict clinical outcomes, including mortality, quality of life, and specific biomarkers 442 443 associated with rare disease. Finally, we used predicted phenotypes from the model to estimate the prevalence of undiagnosed rare disease in the UK Biobank, showing that it is likely extremely high. This 444 445 kind of systematic phenome-wide analysis has not previously been possible for rare diseases, highlighting the utility of RarePT to conduct large-scale studies on rare disease. The high rate of undiagnosed rare 446

It is made available under a CC-BY 4.0 International license .

- 447 disease in large population datasets like the UK Biobank also highlights the need for new methods like
- 448 RarePT to address the problem of undiagnosed rare disease and suggests a wide range of valuable clinical
- 449 and research applications.
- 450
- Author Contributions: Dr. Jordan and Dr. Do had full access to all of the data in the study and take 451
- 452 responsibility for the integrity of the data and accuracy of the data analysis.
- 453 Concept and design: Jordan, Do.
- Acquisition, analysis, or interpretation of the data: Jordan, Vy, Do. 454
- 455 Drafting of the manuscript: Jordan, Do.
- 456 Critical revision of the manuscript for important intellectual concept: Jordan, Do.
- Statistical analysis: Jordan. 457
- Administrative, technical, or material support: Do 458

459 *Supervision:* Do.

460

461	Conflict of Interest Disclosures: Dr. Do reported receiving grants from AstraZeneca, grants and non-
462	financial support from Goldfinch Bio, being a scientific co-founder, consultant and equity holder for
463	Pensieve Health (pending), and being a consultant for Variant Bio, all not related to this study.
464	
465	Materials and Correspondence: Requests for materials and correspondence should be addressed to Dr.
466	Do.

. .

467

It is made available under a CC-BY 4.0 International license .

468	Data availability statement: Summary data required to generate figures will be deposited in a public
469	repository prior to publication, and are available on request from the authors otherwise. Individual-level
470	data from the UK Biobank and the Mount Sinai Data Warehouse are governed by third-party data use
471	agreements and cannot be made available with this study. Researchers who qualify for access to
472	deidentified data under the policies of the UK Biobank and/or the Mount Sinai Health System can access
473	these data upon application to the respective institutions.
474	
475	Code availability statement: Code required to train all models, run all analyses, and generate all figures
476	will be published in a public repository under an open-source license prior to publication, and is available
477	upon request from the authors otherwise.
478	
479	Funding/Support: Dr. Do is supported by the National Institute of General Medical Sciences of the NIH
480	(R35-GM124836). This research has been conducted using the UK Biobank Resource under Application
481	Number 16218. This work was supported in part through the Mount Sinai Data Warehouse (MSDW)
482	resources and staff expertise provided by Scientific Computing and Data at the Icahn School of Medicine
483	at Mount Sinai.
484	
485	Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the



487

It is made available under a CC-BY 4.0 International license .

488 Methods

489 *Data collection and preprocessing*

490 The primary training data were derived from the UK Biobank⁷³. For each participant, we retrieved age at recruitment (field 21022), sex (field 31), and a list of all ICD-10 diagnosis codes recorded 491 492 across all inpatient hospital records (field 41270). We also retrieved self-reported ethnicity (field 21000), body mass index (BMI, field 21001), blood pressure (fields 4079-4080), LDL cholesterol (field 30780), 493 494 total cholesterol (field 30690), blood glucose (field 30740), and glycated hemoglobin (HbA_{1C}, field 495 30750) as baseline cohort characteristics (shown in Table 1), and 23 diagnostic tests and biomarkers assayed as part of the recruitment process (Supplementary Table S6), though these were not included in 496 497 the data used to train the model. For this study, we represented each ICD-10 code as a binary indicator that could either be present or absent, ignoring the dates associated with each code. We mapped ICD-10 498 codes to version 1.2 of the Phecode classification, using the published mapping²⁴. This resulted in a 499 500 dataset of 436,407 participants, 239,711 female and 196,696 male, including 1,558 of the 1,570 phecodes 501 with defined ICD-10 code mappings. Demographic and clinical characteristics of this cohort are shown in 502 Table 1.

We constructed a balanced dataset of training examples consisting of 100 cases and 100 controls 503 504 of each phecode, excluding phecodes with fewer than 100 cases or fewer than 100 controls. This excluded 273 phecodes, leaving 1,297 unique query phecodes. These 273 phecodes remained in the training data as 505 506 diagnoses but were never used as the query in any training examples. Cases were defined as participants 507 whose phecode diagnoses contained the query phecode. Controls were defined as participants whose phecode diagnoses did not include the query phecode or any phecodes listed as exclusions for the query 508 509 phecode. For sex-specific phecodes, controls were also required to be the correct sex for the query 510 phecode. For cases, the query phecode and all exclusion phecodes were removed from the diagnosis list 511 as part of preprocessing (Figure 1a). Phecode diagnoses were encoded using a many-hot encoding, with

It is made available under a CC-BY 4.0 International license .

phecodes ordered linearly by their numerical code; query phecodes were encoded using a one-hotencoding with the same ordering of phecodes.

Training examples were randomly split into five equal subsets for five-fold cross validation. Since the same individual can appear multiple times with different query phecodes, we required each cross-validation subset to contain a unique set of individuals, so that each individual can only appear in one subset. This prevents the model from improving performance by recognizing specific individuals from the training set and recapitulating the known diagnoses of those individuals. Cross-validation subsets were also required to contain similar numbers of cases and controls.

Our independent validation data were derived from the Mount Sinai Data Warehouse (MSDW), a 520 521 database of clinical and operational data derived from the electronic health records (EHR) systems of the Mount Sinai Health System in New York City. These data are anonymized, standardized, and 522 523 preprocessed for use in clinical and translational research. For each patient in this database, we retrieved age as of 2009 (the median date associated with the "age of recruitment" field in the UK Biobank), 524 525 physician-reported sex, and a list of all ICD-10-CM diagnosis codes recorded in the EHR. We mapped these to phecodes using the published mapping for ICD-10-CM diagnosis codes, which is slightly 526 different from the mapping for the ICD-10 codes used in the UK Biobank²⁴. Patient records were 527 processed into examples suitable for the model in the same way as described above. The final size of this 528 529 cohort was 3,333,560. Demographic and clinical characteristics of this cohort are shown in Table 1. 530 Study protocols were approved by the Institutional Review Board at the Icahn School of Medicine at Mount Sinai (New York City, NY, USA; GCO#07-0529; STUDY-11-01139) and all 531

532 participants provided informed consent. Use of data from the UK Biobank was approved with the UK

533 Biobank Resource under application number 16218.

It is made available under a CC-BY 4.0 International license .

534 *Model architecture, tuning, and training*

The model was implemented in Python using the Keras package⁷⁴. Figure 1a shows a schematic 535 of the model architecture. The input diagnosed phecodes feed into a stack of modified transformer 536 decoder modules, based on the TransformerDecoder layer implemented in the KerasNLP package⁷⁵. The 537 538 standard TransformerDecoder layer was modified to remove the causal attention mask that prevents the self-attention layer from paying attention to positions that are later in the sequence than the token 539 currently being considered. Since the phecode encoding is ordered by phenotype category and we are 540 541 ignoring temporal sequencing, this causal mask would be inappropriate. Each decoder layer also contains 542 a cross-attention layer which takes input from the encoded query phecode, allowing the model to learn attention relationships between the diagnosis phecodes and the query phecode. To adjust for demographic 543 variables, the demographic variables are passed through a single densely connected layer to transform 544 them into the same dimension as the phecodes, and then added to the output of the transformer layers and 545 546 normalized. Finally, the prediction is given by a dot product between the input query phecodes and the 547 demographics-adjusted output of the transformer layer, and transformed into a probability score using a softmax function. The Python code implementing this architecture will be made publicly available along 548 with this publication. 549

Hyperparameter tuning was performed using the Hyperband algorithm, as implemented in the 550 KerasTune package^{25,76}. The list of hyperparameters and their final tuned values are found in 551 552 Supplementary Table S13. We randomly sampled 80% of the training data to use for training and used the remaining 20% as the validation set for the hyperband algorithm, choosing the hyperparameters that 553 554 minimized the training loss function on the validation set. For five-fold cross-validation runs, this 20% 555 held out validation sample was contained within the training set and did not overlap the cross-validation test set. The hyperband algorithm was run for up to 18 epochs per model, stopping if validation loss failed 556 to improve in 5 consecutive epochs. The final selected model was then trained for up to 54 epochs, and 557 558 the best epoch was selected based on validation loss. Finally, after tuning was complete, the held-out

It is made available under a CC-BY 4.0 International license .

559 validation set was added back into the training set and selected model was retrained for the selected 560 number of epochs on the complete training set. Again, the Python code implementing this training procedure will be made publicly available along with this publication. We repeated this hyperparameter 561 562 tuning for each of the five training subsets produced by cross-validation as well as on the full training set, 563 and all six runs selected identical values for all hyperparameters. Models were trained using NVIDIA A100 GPUs on the Mount Sinai local high-performance computing cluster, Minerva. Each cross-564 validation run took approximately 5 hours of GPU time to tune and train, and the full model took 565 approximately 6 hours, for a total of approximately 31 hours. 566

567 *Prediction of rare phenotypes*

We calculated the prevalence of each phecode in the UK Biobank by dividing the number of 568 569 cases by the total number of participants. We identified 155 rare phecodes with prevalence less than 1 in 2,000, or 0.05%, corresponding to the European Union definition of a rare disease. We calculated model 570 571 predictions from each of the six trained models (five cross-validation models and one full-dataset model) 572 using each of these 155 phecodes as a query for 436,407 participants in the UK Biobank, excluding from 573 each model the participants contained in its own training set. We additionally produced predictions from the full trained model for 3,333,560 patients in the MSDW cohort for each of the 151 rare phecodes that 574 were also present in that cohort. Generating model predictions for the UK Biobank cohort took 575 576 approximately 3 hours of GPU time for each of the six models, for a total of approximately 18 hours; generating model predictions for the MSDW cohort took approximately 45 hours of GPU time. The 577 578 MSDW cohort took substantially longer because the dataset was too large for the model to fit into memory and had to be broken up into batches. 579

580 We quantified the performance of our models by diagnostic odds ratios and positive predictive 581 values. We arbitrarily chose a threshold probability score of 0.95 to represent a relatively high-confidence 582 case prediction, and treated predictions with probability score > 0.95 as predicted cases and ≤ 0.95 as

It is made available under a CC-BY 4.0 International license .

(1)

(2)

583 predicted controls. We quantified performance using odds ratio (OR) and positive predictive value (PPV),

as these are measures relevant to diagnostic screening tests²⁹. We calculated OR as

585
$$OR = \frac{(TP + 0.5)/(FP + 0.5)}{(FN + 0.5)/(TN + 0.5)}$$

586

where *TP* is the number of true positive predictions (cases correctly predicted as cases), *FP* is the number of false positive predictions (controls incorrectly predicted as cases), *TN* is the number of true negative predictions (controls correctly predicted as controls), and *FN* is the number of false negative cases. In other words, this is the ratio between the odds of a positive prediction being a case and the odds of a negative prediction being a case. We added a correction of 0.5 to each count to correct for zeros⁷⁷. We calculated PPV as

593
$$PPV = \frac{TP}{TP + FN}$$

594

595 In other words, this is the probability that a positive prediction is a case. In all instances, we excluded 596 controls with an exclusion phecode, controls whose sex did not match the phecode, and all individuals 597 who were included in the training set of the cross-validated models.

598 *Mortality and DALY analyses*

We estimated disability-adjusted life years (DALY) and its components years lost to disability (YLD) and years of life lost (YLL) for UKBB individuals using per-disease estimates from the 2019 Global Burden of Disease (GBD) study. We used the 80 non-overlapping non-communicable diseases that account for the majority of a population's DALY as described by Jukarainen et al.^{32,33} GBD definitions of specific diseases and conditions were used to label individuals affected by these diseases in the UK Biobank. Estimates of disease burden in the UK from GBD were then applied to individuals with each

It is made available under a CC-BY 4.0 International license .

disease to produce estimated values of DALY, YLD, and YLL.³² These estimated values were tested 605 606 against RarePT predictions by linear regression. We retrieved a single prediction score by using the model 607 trained on the full dataset for individuals who were not included in the training set, and the appropriate 608 cross-validation model for individuals who were included in the training set (that is, the cross-validation 609 model whose training set did not include that individual). We turned this score into a binary prediction using an arbitrary threshold of 0.95. We then performed linear regression testing the ability of this score 610 (independent variable) to predict DALY, YLD, or YLL (dependent variable), controlling for age, sex, and 611 612 self-reported ethnicity. We repeated this analysis both including all UK Biobank participants and 613 excluding known diagnosed cases and exclusions for each phecode.

We additionally retrieved date of death and date of recruitment from the UK Biobank (fields 40000 and 53) and performed an analysis of mortality using Cox proportional hazard regression. We treated time from recruitment to death as a right-censored dependent variable, again using the binary RarePT prediction as an independent variable along with age at recruitment, sex, and self-reported ethnicity. As with DALY, we repeated this analysis both including all UK Biobank participants and excluding known diagnosed cases and exclusions for each phecode. All regressions were performed in Python using the statsmodels package⁷⁸.

621 Biomarker and diagnostic test analysis

622 We collected biomarkers and diagnostic tests associated with phecodes using the SNOMED-CT database of clinical terms^{34,35}. We identified all ICD-10 codes that mapped to any of our 155 rare 623 624 phecodes and also mapped to a SNOMED-CT term with an "interprets" relationship (concept 625 363714003). The "interprets" relationship indicates that the concept represented by the diagnosis code has an underlying evaluation that is "intrinsic to the meaning of" that concept⁷⁹. Examples of this kind of 626 627 relationship include the relationship between obesity and measured body weight, hypercholesterolemia 628 and total serum cholesterol, or thrombocytopenia and platelet count. In most cases, SNOMED-CT also 629 identifies the direction of the relationship using the "has interpretation" relationship (concept 363713009).

It is made available under a CC-BY 4.0 International license .

For example, hypercholesterolemia is interpreted as total serum cholesterol above reference range, while thrombocytopenia is interpreted as platelet count below reference range. For each concept that was the target of an "interprets" relationship, we manually searched for a corresponding measurement available in the UK Biobank and a corresponding reference range. The result was a list of 75 relationships between rare phecodes and UK Biobank data fields, encompassing 32 rare phecodes and 23 data fields, each with an expected direction of relationship (above, below, or outside) and sex-specific reference ranges (Supplementary Table S6).

As with the previously described regression analyses, we retrieved a single prediction score for 637 each of these 32 rare phecodes by using the model trained on the full dataset for individuals who were not 638 639 included in the training set, and the appropriate cross-validation model for individuals who were included 640 in the training set (that is, the cross-validation model whose training set did not include that individual). We turned this score into a binary prediction using the same 0.95 threshold. We then performed two 641 642 regression analyses testing the ability of this binary prediction (independent variable) to predict the 643 corresponding data field (dependent variable), controlling for age, sex, and self-reported ethnicity. In the first analysis, we used the expected direction of relationship and the reference range to construct a binary 644 645 variable indicating whether each individual had an abnormal result in the direction expected. We performed logistic regression using this binary variable as the dependent variable. We repeated this 646 647 analysis both including all participants and excluding individuals labelled as cases or exclusions for each phecode. This regression tests whether the model can predict individuals with abnormal test results 648 consistent with a diagnosis even in individuals labelled as controls. In the second analysis, we normalized 649 650 the values of each biomarker within the reference range so that the sample population for each sex had 651 mean 0 and variance 1 after excluding all individuals with values outside the reference range. Finally, we aligned the values so that the expected direction of association was always positive, by multiplying them 652 by -1 for "below reference range" relationships and taking their absolute value for "outside reference 653 654 range" relationships. We performed standard linear regression using this normalized and aligned value as

It is made available under a CC-BY 4.0 International license .

the dependent variable. We repeated this analysis both including all participants and excluding both
individuals labelled as cases or exclusions and individuals with abnormal test results. This regression tests
whether the model can predict individuals with elevated or reduced results even if they are still within the
normal range. Regressions were performed in Python using the statsmodels package⁷⁸.
Finally, we identified a set of "confirmed controls" for each phecode, defined as individuals labelled as
controls who also had all associated results within the reference range and within one standard deviation

of the population mean for their sex. We consider these individuals very unlikely to be undiagnosed cases

662 incorrectly labelled as controls. We used the performance of our model on these confirmed controls to

estimate the false positive rate of our model for each of the 32 phecodes with available relationships to

test results. We then used this false positive rate to estimate the number of undiagnosed cases using thefollowing relationship:

$$P_u = \frac{UP - FPR \times U}{TPR - FPR}$$

667 Where P_u represents the number of undiagnosed cases; *U* represents the total number of individuals with 668 unknown case-control status, excluding controls confirmed by laboratory tests but including undiagnosed 669 cases; *UP* represents the total number of unknowns predicted as cases by the model, again excluding 670 controls confirmed by laboratory tests but including undiagnosed cases; *FPR* represents the false positive 671 rate of the model as estimated from confirmed controls; and *TPR* represents the true positive rate of the 672 model as estimated from diagnosed cases. See **Supplementary Note 1** for derivation and discussion of 673 this relationship.

674 The Python code implementing all these analyses will be made publicly available along with this675 publication.

676 Software Package and Workflow

It is made available under a CC-BY 4.0 International license .

For portability and reproducibility, model training and analysis code is formatted as a Snakemake

678	workflow.80 This allows easy retraining of the RarePT model and reproduction of the analyses reported
679	here on any appropriately-formatted individual-level dataset. After creating an appropriately named and
680	formatted input data file and setting up Snakemake for their execution environment, users can train a new
681	model with a single command:
682	snakemake
683	<pre>results/models/my_dataset.100_case_control_sample.full_from_5_fold_cv.</pre>
684	seed_18
685	The number of cases and controls sampled, the number of cross-validation folds used for testing, and the
686	random seed can be changed by changing the appropriate values in the targeted filename. Likewise,
687	snakemake
688	<pre>results/data/my_dataset.100_case_control_sample.5_fold_cv.seed_18.all_</pre>
689	rare_predictions_with_cv.parquet
690	trains a model and uses cross-validation to generate model predictions for all rare phecodes, and
691	snakemake
692	results/data/uk_biobank.100_case_control_sample.full_from_5_fold_cv.se
693	ed_18.vs.my_dataset.all_rare_predictions.parquet
694	uses the UK Biobank trained model to generate model predictions for all rare phecodes in a user dataset.
695	Snakemake can be configured for many different high-performance computing and cloud computing
696	environments and, when properly configured, automatically manages resource requirements and package
697	dependencies.
698	The Snakemake workflow will be published with acceptance of this manuscript in a peer-
699	reviewed journal. Prior to formal publication, it is available on request from the authors.
700	

It is made available under a CC-BY 4.0 International license .

701

702

It is made available under a CC-BY 4.0 International license .

703 Table 1. Baseline demographic and clinical characteristics of cohorts.

Characteristic		No. (%)		
		UK Biobank	Mount Sinai Data	
		(N=436,407)	Warehouse	
			(N=3,333,560)	
Women		239,611 (55%)	1,861,995 (56%)	
Men		196,696 (45%)	1,471,565 (44%)	
Age, mean	n (SD), yrs	57 (8)	33 (22)	
Self-	White	411,074 (94%)	1,118,704 (34%)	
Reported	Black	6,900 (1.6%)	385,815 (12%)	
Race	Asian	9,695 (2.2%)	185,233 (5.6%)	
and/or	Hispanic or Latino	0 (0%)	367,924 (11%)	
Ethnicity	Multiple, Other, or Unknown	8,738 (2.0%)	383,984 (12%)	
BMI, mean (SD), kg/m ²		27 (5)	26 (7)	
SBP, mean (SD), mmHg		138 (19)	123 (17)	
DBP, mean (SD), mmHg		82 (11)	74 (10)	
LDL-C, mean (SD), mg/dL		138 (34)	101 (35)	
Total cholesterol, mean (SD), mg/dL		220 (45)	181 (45)	
HbA _{1c} , median (IQR), %		5.5 (0.4)	5.6 (1.6)	
Glucose, mean (SD), mg/dL		92 (22)	132 (55)	
Hypertension (phecode 401)		151,254 (34%)	497,655 (15%)	
Type 2 Diabetes (phecode 250.2)		42,335 (9.7%)	211,779 (6.4%)	
Breast Cancer (phecode 174)		436,407 (5.2%)	43,212 (1.3%)	

It is made available under a CC-BY 4.0 International license .

704	BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, LDL-C = LDL
705	cholesterol, HbA_{1c} = Hemoglobin A_{1c} . For the UK Biobank cohort, demographic characteristics, vitals,
706	and blood tests were measured at recruitment. In the Mount Sinai Data Warehouse cohort, there was no
707	distinct recruitment visit, so individual ages were measured as age in 2009, which corresponds to the
708	median recruitment date for the UK Biobank cohort, and individual vitals and blood tests were measured
709	as the mean across all available measurements from each individual's electronic health records (EHR). In
710	both cohorts, diagnoses were measured using phecodes derived from the presence or absence of specific
711	ICD-10 or ICD-10-CM diagnosis codes across each individual's EHR; see methods for details.

712

713

It is made available under a CC-BY 4.0 International license .

714 Figure 1. Schematics of masked phenotype modeling training procedure and RarePT model

715 architecture.



716 (a) Masked phenotype modeling training procedure. Each individual is represented by demographic 717 characteristics (age and sex) and the set of all diagnoses present in their EHR across all encounters, represented as phecodes. A single training example consists of all demographic characteristics, a "query" 718 719 phecode indicating the phecode to be trained on, and the target case/control designation. The example is 720 considered a "Case" if the individual's EHR contains the query phecode, "Unknown" if the individual's EHR does not contain the query phecode but does contain a phecode defined as an exclusion for the query 721 phecode, and "Control" if the individual's EHR contains neither the query phecode nor any phecode 722 defined as an exclusion for the query phecode. In all instances, the query phecode and all phecodes 723 defined as exclusions for the query phecode are hidden before training or prediction. (b) Rare-Phenotype 724 Prediction Transformer (RarePT) architecture. We apply a simplified transformer architecture to the 725

It is made available under a CC-BY 4.0 International license .

- 726 diagnoses. Diagnoses are fed into a transformer decoder in a many-hot encoding, in a single step with no
- sequence. The transformer decoder consists of a self-attention layer, a cross-attention attending to the
- 728 query phecode, and a feed-forward layer, all connected by residual skip connections, as in the standard
- transformer architecture. Demographic characteristics are interpreted by a dense linear layer and then
- applied as an adjustment to the transformer output. The final prediction is the dot product of the query
- 731 phecode input with the demographic-adjusted transformer output.

732

It is made available under a CC-BY 4.0 International license .

Figure 2. Performance of RarePT to predict diagnosed cases of 155 rare phecodes.



734



(a) Box and whisker plots showing distribution of diagnostic odds ratio (ratio of odds in predicted cases 736 to odds in predicted controls) across rare phecodes. The five blue boxes labelled "UKBB/CV1-5" show 737 the performance of the five models trained using five-fold cross-validation within the UK Biobank, 738 excluding each model's training set; median OR across all five cross-validation sets was 48 (full range 739 1.27-39,000). The orange box labeled "MSDW" shows the performance of the model trained using the 740 741 full UK Biobank dataset on the Mount Sinai Data Warehouse dataset, an independent cohort from the Mount Sinai Health System in New York; median OR for this cohort was 31 (full range 0.41-4,600). 742 Performance on the independent dataset is only slightly reduced, despite extensive differences between 743

It is made available under a CC-BY 4.0 International license .

744 these datasets and health systems, demonstrating the robustness of the approach. Boxes show 1st quartile, 745 median, and 3rd quartile; whiskers extend to 80% of interquartile range; dashed line shows random chance. (b) Heatmap showing odds ratios (median across five-fold cross-validation) for distinguishing 746 between diagnosed cases of one phecode and diagnosed cases of a second phecode. Columns represent 747 748 different case phecodes, rows represent different control phecodes, both ordered so that phecodes in the same biological category are grouped together. For each cell, the RarePT models trained in cross-749 validation were presented with a dataset consisting of all diagnosed cases of both phecodes in UK 750 751 Biobank, excluding the model's own training set. The model was asked to predict case status for the case 752 phecode, treating cases of the control phecode as controls. Red indicates that the model's case predictions are enriched for cases of the correct phecode, while blue indicates that the model's case predictions are 753 754 depleted for cases of the correct phecode. Blank (white) cells indicate phecodes that are labelled as exclusions in the definition of the target phecode. While some comparisons are more successful than 755 756 others, mostly depending on the identity of the phecode used as controls, RarePT successfully predicts cases across a wide range of rare phecodes, even when the background is cases for other rare phecodes. 757 Blue This demonstrates that RarePT's predictions are specific to each specific phecode, and are not 758 primarily predicting categories of diagnoses or general health. (c) Scatterplot comparing RarePT's 759 760 performance for rare phecodes on UK Biobank and Mount Sinai Data Warehouse cohorts. Each data 761 point represents a single phecode; horizontal error bars represent the results of five-fold cross validation within the UK Biobank cohort. Performance for specific phecodes is strongly correlated between cohorts 762 (Pearson r = 0.456, p = 5.03×10^{-40} , t-test), demonstrating that the specific features used to differentiate 763 764 different phecodes are robust to differences between cohorts, including differences in diagnosis coding, recruitment, and ethnic and racial composition. Dashed lines show random chance within each cohort; 765 dotted line shows equal performance between cohorts. 766

767

768

769

It is made available under a CC-BY 4.0 International license .

Figure 3. Estimated performance of RarePT to predict undiagnosed cases of 32 rare phecodes with



771 available relevant laboratory tests.

It is made available under a CC-BY 4.0 International license .

773 (a-b) Regression analysis showing RarePT predicts diagnostic test results in UK Biobank participants. 774 Plots show number of significant regressions after Bonferroni correction for 75 tests in known relevant diagnostic tests (red dashed lines) and 100 random permutations of test-disease relationships (blue boxes). 775 776 X axis shows logistic regression of abnormal test results vs. RarePT prediction, while Y axis shows linear 777 regression of quantitative test results vs. RarePT prediction, both controlling for age at recruitment, sex, 778 and self-reported ethnicity. Panel a shows results among all UK Biobank participants; Panel b excludes known cases, and the Y axis of panel b additionally excludes participants with abnormal test results. For 779 780 both analyses, the number of significant regressions were lower than the actual observed results for all 781 100 permutations in both analyses. This demonstrates that RarePT predicts relevant clinical features of 782 disease, not only the presence of a diagnosis. Individuals with a positive prediction from RarePT but no 783 diagnosis likely have phenotypic profiles that are similar to the predicted rare diagnosis, and may include undiagnosed cases. (c) Illustration of estimation of undiagnosed cases. All individuals can be classified as 784 785 known cases with EHR diagnosis, known controls with confirmed normal test results (defined as 786 participants within 1 standard deviation of the population mean for all tests associated with a given 787 phecode), or unknown. Unknown individuals are a mixture of undiagnosed cases and unconfirmed 788 controls in an unknown proportion. We assume that the behavior of the model on unknown individuals 789 ("unknown positive rate") is a mixture of its behavior on cases ("true positive rate") and controls ("false 790 positive rate"). With this assumption, we estimate the proportion of cases and controls in the unknown 791 group based on the relationship between these three positive prediction rates. See Supplementary Note 1 for discussion and derivation of this relationship. (d-e) Number of undiagnosed cases and fraction of 792 793 cases undiagnosed for 32 rare phecodes, estimated from RarePT's performance on known cases and 794 controls. Error bars represent bootstrap 95% confidence intervals. While the presence of undiagnosed 795 cases detected by RarePT varies across different rare phecodes, a majority of phecodes tested have an 796 estimate above zero, and half are estimated to have a higher number of undiagnosed cases than diagnosed 797 cases. This highlights the importance of developing methods to screen for undiagnosed cases of rare 798 disease.

It is made available under a CC-BY 4.0 International license .

800 List of Supplementary Items

- 801 Supplementary Note S1. Estimation of undiagnosed cases.
- 802 Supplementary Figure S1. Receiver operating characteristic (ROC) curves for training and testing cross-
- 803 validation datasets in UK Biobank.
- 804 Supplementary Figure S2. Positive predictive value of RarePT predictions for 155 rare phecodes in UK
- 805 Biobank and MSDW cohorts.
- 806 Supplementary Table S1. Cross-validation performance metrics for training and testing.
- 807 Supplementary Table S2. List of 155 rare phecodes in UK Biobank and Mount Sinai Data Warehouse.
- 808 Supplementary Table S3. Model performance by phecode for 155 rare phecodes in UK Biobank cohort.
- 809 Supplementary Table S4. Model performance by phecode for 151 rare phecodes in MSDW cohort.
- 810 Supplementary Table S5. Regression results for mortality, DALY, and related measures.
- 811 Supplementary Table S6. List of diagnostic tests relevant to rare phecodes.
- 812 Supplementary Table S7. Regression results for 75 diagnostic tests known to be relevant to rare
- 813 phecodes.

814 Supplementary Table S8. Regression results for 100 permutations of phecode-test relationships.

815 Supplementary Table S9. Regression results for mortality, DALY, and related measures in controls only.

- 816 Supplementary Table S10. Regression results for 75 diagnostic tests known to be relevant to rare
- 817 phecodes in controls only.
- 818 Supplementary Table S11. Regression results for 100 permutations of phecode-test relationships in819 controls only.
- 820 Supplementary Table S12. Estimated numbers of undiagnosed cases for 32 rare phecodes.

It is made available under a CC-BY 4.0 International license .

821 Supplementary Table S13. Description of model hyperparameters and final tuned values.

822

It is made available under a CC-BY 4.0 International license .

823 References

1. Herder, M. What Is the Purpose of the Orphan Drug Act? *PLOS Med.* **14**, e1002191 (2017).

Richter, T. *et al.* Rare Disease Terminology and Definitions — A Systematic Global Review: Report
of the ISPOR Rare Disease Special Interest Group. *Value Health* 18, 906–914 (2015).

827 3. Ferreira, C. R. The burden of rare diseases. *Am. J. Med. Genet. A.* **179**, 885–892 (2019).

4. Jaffe, A., Zurynski, Y., Beville, L. & Elliott, E. Call for a national plan for rare diseases. *J. Paediatr. Child Health* 46, 2–4 (2010).

Nutt, S. & Limb, L. Survey of patients' and families' experiences of rare diseases reinforces calls
for a rare disease strategy. *Soc. Care Neurodisability* 2, 195–199 (2011).

832 6. Molster, C. *et al.* Survey of healthcare experiences of Australian adults living with rare diseases.
833 *Orphanet J. Rare Dis.* **11**, 30 (2016).

Azzariti, D. R. & Hamosh, A. Genomic Data Sharing for Novel Mendelian Disease Gene Discovery:
The Matchmaker Exchange. *Annu. Rev. Genomics Hum. Genet.* 21, 305–326 (2020).

Philippakis, A. A. *et al.* The Matchmaker Exchange: A Platform for Rare Disease Gene Discovery.
 Hum. Mutat. 36, 915–921 (2015).

Boycott, K. M., Azzariti, D. R., Hamosh, A. & Rehm, H. L. Seven years since the launch of the
Matchmaker Exchange: The evolution of genomic matchmaking. *Hum. Mutat.* 43, 659–667 (2022).

Laurie, S. *et al.* The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis,
research, and gene discovery for rare diseases. *Hum. Mutat.* 43, 717–733 (2022).

Hsieh, T.-C. *et al.* GestaltMatcher: Overcoming the limits of rare disease matching using facial
phenotypic descriptors. 2020.12.28.20248193 Preprint at https://doi.org/10.1101/2020.12.28.20248193
(2021).

Frederiksen, S. D. *et al.* Rare disorders have many faces: in silico characterization of rare disorder
spectrum. *Orphanet J. Rare Dis.* **17**, 76 (2022).

Koroteev, M. V. BERT: A Review of Applications in Natural Language Processing and
Understanding. Preprint at https://doi.org/10.48550/arXiv.2103.11943 (2021).

849 14. Zhang, M. & Li, J. A commentary of GPT-3 in MIT Technology Review 2021. *Fundam. Res.* 1, 831–
850 833 (2021).

15. Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583– 589 (2021).

853 16. Cheng, J. *et al.* Accurate proteome-wide missense variant effect prediction with AlphaMissense.
854 *Science* **0**, eadg7492 (2023).

Ma, A. *et al.* Single-cell biological network inference using a heterogeneous graph transformer. *Nat. Commun.* 14, 964 (2023).

18. Avsec, Ž. *et al.* Effective gene expression prediction from sequence by integrating long-range
interactions. *Nat. Methods* 18, 1196–1203 (2021).

859 19. Devlin, J., Chang, M.-W., Lee, K. & Toutanova, K. BERT: Pre-training of Deep Bidirectional

860 Transformers for Language Understanding. in *Proceedings of the 2019 Conference of the North American*

861 Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long

and Short Papers) 4171–4186 (Association for Computational Linguistics, 2019). doi:10.18653/v1/N191423.

20. Yu, W. *et al.* Dict-BERT: Enhancing Language Model Pre-training with Dictionary. Preprint at https://doi.org/10.48550/arXiv.2110.06490 (2022).

Liu, Q., McCarthy, D. & Korhonen, A. Second-order contexts from lexical substitutes for few-shot
learning of word representations. in *Proceedings of the Eighth Joint Conference on Lexical and Computational Semantics (*SEM 2019)* 61–67 (Association for Computational Linguistics, 2019).
doi:10.18653/v1/S19-1007.

Schick, T. & Schütze, H. BERTRAM: Improved Word Embeddings Have Big Impact on
Contextualized Model Performance. Preprint at http://arxiv.org/abs/1910.07181 (2020).

872 23. Bastarache, L. Using Phecodes for Research with the Electronic Health Record: From PheWAS to
873 PheRS. *Annu. Rev. Biomed. Data Sci.* 4, 1–19 (2021).

Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and
Initial Evaluation. *JMIR Med. Inform.* 7, e14325 (2019).

Li, L., Jamieson, K., DeSalvo, G., Rostamizadeh, A. & Talwalkar, A. Hyperband: A Novel BanditBased Approach to Hyperparameter Optimization. *J. Mach. Learn. Res.* 18, 6765–6816 (2017).

878 26. Fry, A. *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank
879 Participants With Those of the General Population. *Am. J. Epidemiol.* 186, 1026–1034 (2017).

Schoeler, T. *et al.* Participation bias in the UK Biobank distorts genetic associations and
downstream analyses. *Nat. Hum. Behav.* 7, 1216–1227 (2023).

Hilton, B. *et al.* Laboratory diagnosed microbial infection in English UK Biobank participants in
comparison to the general population. *Sci. Rep.* 13, 496 (2023).

29. Deeks, J. J. Systematic reviews of evaluations of diagnostic and screening tests. *BMJ* **323**, 157– 162 (2001).

30. Glas, A. S., Lijmer, J. G., Prins, M. H., Bonsel, G. J. & Bossuyt, P. M. M. The diagnostic odds ratio: a
single indicator of test performance. *J. Clin. Epidemiol.* 56, 1129–1135 (2003).

888 31. Beesley, L. J. *et al.* The emerging landscape of health research based on biobanks linked to
889 electronic health records: Existing resources, statistical challenges, and potential opportunities. *Stat.*890 *Med.* **39**, 773–800 (2020).

32. Jukarainen, S. *et al.* Genetic risk factors have a substantial impact on healthy life years. *Nat. Med.*28, 1893–1901 (2022).

It is made available under a CC-BY 4.0 International license .

33. Vos, T. *et al.* Global burden of 369 diseases and injuries in 204 countries and territories, 1990–
2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* **396**, 1204–1222
(2020).

896 34. Millar, J. The Need for a Global Language - SNOMED CT Introduction. *Stud. Health Technol.*897 *Inform.* 225, 683–685 (2016).

Wasserman, H. & Wang, J. An Applied Evaluation of SNOMED CT as a Clinical Vocabulary for the
Computerized Diagnosis and Problem List. *AMIA. Annu. Symp. Proc.* 2003, 699–703 (2003).

36. Agniel, D., Kohane, I. S. & Weber, G. M. Biases in electronic health record data due to processes
within the healthcare system: retrospective observational study. *BMJ* 361, k1479 (2018).

902 37. Forrest, I. S. *et al.* Genetic and phenotypic profiling of supranormal ejection fraction reveals
903 decreased survival and underdiagnosed heart failure. *Eur. J. Heart Fail.* 24, 2118–2127 (2022).

38. Appadurai, V. *et al.* Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by
analysis of ~60,000 human exomes. *Mol. Genet. Metab.* **116**, 298–304 (2015).

906 39. Dickey, A. K. *et al.* Evidence in the UK Biobank for the underdiagnosis of erythropoietic
907 protoporphyria. *Genet. Med.* 23, 140–148 (2021).

908 40. Shoemark, A. *et al.* Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in
909 bronchiectasis. *Eur. Respir. J.* **60**, (2022).

910 41. Damrauer, S. M. *et al.* Association of the V122I Hereditary Transthyretin Amyloidosis Genetic
911 Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry. *JAMA* 322, 2191–
912 2202 (2019).

42. Anderson, J. J. *et al.* Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank:
implications for screening. *BMJ Open Diabetes Res. Care* 9, e002176 (2021).

915 43. Sturm, A. C. *et al.* Clinical Genetic Testing for Familial Hypercholesterolemia. *J. Am. Coll. Cardiol.*916 **72**, 662–680 (2018).

44. An, U., Cai, N., Dahl, A. & Sankararaman, S. AutoComplete: Deep Learning-Based Phenotype
Imputation for Large-Scale Biomedical Data. in *Research in Computational Molecular Biology* (ed. Pe'er,
1.) 385–386 (Springer International Publishing, 2022). doi:10.1007/978-3-031-04749-7_38.

920 45. Stekhoven, D. J. & Bühlmann, P. MissForest—non-parametric missing value imputation for
921 mixed-type data. *Bioinformatics* 28, 112–118 (2012).

46. Li, R., Chen, Y. & Moore, J. H. Integration of genetic and clinical information to improve
imputation of data missing from electronic health records. J. Am. Med. Inform. Assoc. 26, 1056–1063
(2019).

925 47. Shaw, D. M. *et al.* Phenome risk classification enables phenotypic imputation and gene discovery
926 in developmental stuttering. *Am. J. Hum. Genet.* **108**, 2271–2283 (2021).

927 48. Bernardini, M., Doinychko, A., Romeo, L., Frontoni, E. & Amini, M.-R. A novel missing data
928 imputation approach based on clinical conditional Generative Adversarial Networks applied to EHR
929 datasets. *Comput. Biol. Med.* 163, 107188 (2023).

930 49. Beaulieu-Jones, B. K. *et al.* Characterizing and Managing Missing Structured Data in Electronic
931 Health Records: Data Analysis. *JMIR Med. Inform.* 6, e8960 (2018).

932 50. Wells, B. J., Chagin, K. M., Nowacki, A. S. & Kattan, M. W. Strategies for Handling Missing Data in
933 Electronic Health Record Derived Data. *eGEMs* 1, 1035 (2013).

934 51. Madden, J. M., Lakoma, M. D., Rusinak, D., Lu, C. Y. & Soumerai, S. B. Missing clinical and
935 behavioral health data in a large electronic health record (EHR) system. *J. Am. Med. Inform. Assoc.* 23,
936 1143–1149 (2016).

52. Köpcke, F. *et al.* Evaluation of data completeness in the electronic health record for the purpose
of patient recruitment into clinical trials: a retrospective analysis of element presence. *BMC Med. Inform. Decis. Mak.* 13, 1–8 (2013).

940 53. Hripcsak, G. & Albers, D. J. Next-generation phenotyping of electronic health records. *J. Am.*941 *Med. Inform. Assoc.* 20, 117–121 (2013).

942 54. Abul-Husn, N. S. *et al.* Genetic identification of familial hypercholesterolemia within a single U.S.
943 health care system. *Science* **354**, (2016).

944 55. Marwaha, S., Knowles, J. W. & Ashley, E. A. A guide for the diagnosis of rare and undiagnosed
945 disease: beyond the exome. *Genome Med.* 14, 23 (2022).

946 56. Basile, A. O. & Ritchie, M. D. Informatics and machine learning to define the phenotype. *Expert*947 *Rev. Mol. Diagn.* 18, 219–226 (2018).

948 57. Onnela, J.-P. Opportunities and challenges in the collection and analysis of digital phenotyping
949 data. *Neuropsychopharmacology* 46, 45–54 (2021).

950 58. McArthur, E., Bastarache, L. & Capra, J. A. Linking rare and common disease vocabularies by 951 mapping between the human phenotype ontology and phecodes. *JAMIA Open* **6**, ooad007 (2023).

952 59. Kingdom, R. *et al.* Rare genetic variants in genes and loci linked to dominant monogenic
953 developmental disorders cause milder related phenotypes in the general population. *Am. J. Hum. Genet.*954 **109**, 1308–1316 (2022).

955 60. Bakker, O. B. *et al. Linking common and rare disease genetics through gene regulatory networks*.
956 2021.10.21.21265342 https://www.medrxiv.org/content/10.1101/2021.10.21.21265342v2 (2021)
957 doi:10.1101/2021.10.21.21265342.

861. Köhler, S. *et al.* The Human Phenotype Ontology in 2021. *Nucleic Acids Res.* 49, D1207–D1217
959 (2021).

960 62. Vasant, D. *et al. ORDO: An Ontology Connecting Rare Disease, Epidemiology and Genetic Data*.961 (2014).

It is made available under a CC-BY 4.0 International license .

962 63. Connolly, B. *et al.* Natural Language Processing – Overview and History. in *Pediatric Biomedical*963 *Informatics: Computer Applications in Pediatric Research* (ed. Hutton, J. J.) 203–230 (Springer, 2016).
964 doi:10.1007/978-981-10-1104-7_11.

965 64. Smoller, J. W. The use of electronic health records for psychiatric phenotyping and genomics.
966 Am. J. Med. Genet. B Neuropsychiatr. Genet. 177, 601–612 (2018).

967 65. Griggs, R. C. *et al.* Clinical research for rare disease: Opportunities, challenges, and solutions.
968 *Mol. Genet. Metab.* 96, 20–26 (2009).

969 66. Stoller, J. K. The Challenge of Rare Diseases. *Chest* **153**, 1309–1314 (2018).

- 970 67. Banerjee, J. *et al.* Machine learning in rare disease. *Nat. Methods* 1–12 (2023)
 971 doi:10.1038/s41592-023-01886-z.
- 972 68. De Freitas, J. K. *et al.* Phe2vec: Automated disease phenotyping based on unsupervised 973 embeddings from electronic health records. *Patterns* **2**, 100337 (2021).

69. Kane, M. J. *et al.* A Compressed Language Model Embedding Dataset of ICD 10 CM Descriptions.
2023.04.24.23289046 Preprint at https://doi.org/10.1101/2023.04.24.23289046 (2023).

976 70. Sanjak, J., Zhu, Q. & Mathé, E. A. Clustering rare diseases within an ontology-enriched
977 knowledge graph. 2023.02.15.528673 Preprint at https://doi.org/10.1101/2023.02.15.528673 (2023).

978 71. Xie, F. *et al.* Deep learning for temporal data representation in electronic health records: A
979 systematic review of challenges and methodologies. *J. Biomed. Inform.* **126**, 103980 (2022).

72. Kraljevic, Z. et al. Foresight - Generative Pretrained Transformer (GPT) for Modelling of Patient
 73. Timelines using EHRs. (2022). doi:10.48550/arXiv.2212.08072.

982 73. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide
983 Range of Complex Diseases of Middle and Old Age. *PLOS Med.* **12**, e1001779 (2015).

984 74. Chollet, F. & et al. Keras. (2015).

985 75. Watson, M., Qian, C., Bischof, J., Chollet, F. & et al. KerasNLP. (2022).

986 76. O'Malley, T., Bursztein, E., Long, J., Chollet, F. & et al. KerasTuner. (2019).

987 77. Gart, J. J. Alternative Analyses of Contingency Tables. J. R. Stat. Soc. Ser. B Methodol. 28, 164–
988 179 (1966).

989 78. Seabold, S. & Pertkold, J. statsmodels: Econometric and statistical modeling with python. in
 990 Proceedings of the 9th Python in Science Conference (2010).

- 991 79. International Health Terminology Standards Development Organisation,. SNOMED-CT Editorial992 Guide. http://snomed.org/eg.
- 993 80. Mölder, F. et al. Sustainable data analysis with Snakemake. Preprint at

994 https://doi.org/10.12688/f1000research.29032.2 (2021).